-
公开(公告)号：WO2022139680A1
公开(公告)日：2022-06-30
申请号：PCT/SG2021/050801
申请日：2021-12-17
Inventor： KURAMOCHI, Taichi , KAGEJI, Nagisa , GAN, Siok Wan , WANG, Cheng-I , WANG, Bei , LEE, Wen-Hsin
IPC: C07K16/10 , A61K39/395 , G01N33/53 , A61P31/14
Abstract: The present disclosure provides affinity matured SARS-CoV-2 antibodies with improved physiochemical property derived from a parent antibody that binds to the RBD domain of the SARS-CoV-2 spike protein. Said antibodies can also bind to SARS-CoV-2 protein muteins and have increased solubility. It further discloses a pharmaceutical composition comprising said antibodies and the use of said antibodies for treating and preventing SARS-CoV-2 infection, and for diagnosis of SARS-CoV-2.
-
公开(公告)号：WO2021207433A2
公开(公告)日：2021-10-14
申请号：PCT/US2021/026286
申请日：2021-04-07
Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH , CHENG, Yifan , ASARNOW, Daniel , CRAIK, Charles , MANGLIK, Aashish , BOHN, Markus , WANG, Cheng-I , HU, Yuanyu , WANG, Bei
Inventor： CHENG, Yifan , ASARNOW, Daniel , CRAIK, Charles , MANGLIK, Aashish , BOHN, Markus , WANG, Cheng-I , HU, Yuanyu , WANG, Bei
IPC: C07K16/10 , C07K16/08 , A61P31/12 , A61K39/215 , A61P31/14 , C07K2317/21 , C07K2317/55 , C07K2317/76 , C07K2317/92 , G01N33/53
Abstract: The invention provides novel anti-SARS-CoV-2-Spike antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions.
-
公开(公告)号：WO2017021540A1
公开(公告)日：2017-02-09
申请号：PCT/EP2016/068780
申请日：2016-08-05
Inventor： WANG, Cheng-I , BRAUER, Peter , YEO, Siok Ping , TAN, Hwee Ching , CONNOLLY, John Edward
CPC classification number: A61K39/3955 , A61K2039/505 , A61K2039/57 , C07K16/2866 , C07K16/468 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/60 , C07K2317/622 , C07K2317/64 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00
Abstract: Anti-CD122 and/or γc antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
Abstract translation: 公开了抗CD122和/或γc抗体及其片段。 还公开了包含这种抗体和片段的组合物，以及使用它们的用途和方法。
-
公开(公告)号：WO2013089647A1
公开(公告)日：2013-06-20
申请号：PCT/SG2012/000477
申请日：2012-12-17
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor： FINK, Katja , WANG, Cheng-I
CPC classification number: C07K16/1081 , C07K2317/10 , C07K2317/31 , C07K2317/33 , C07K2317/76 , G01N33/54306 , G01N2333/47
Abstract: The present invention relates to binding molecules suited to the diagnosis, prevention and/or treatment of dengue virus infection.
Abstract translation: 本发明涉及适合于登革热病毒感染的诊断，预防和/或治疗的结合分子。
-
公开(公告)号：WO2021206636A1
公开(公告)日：2021-10-14
申请号：PCT/SG2021/050195
申请日：2021-04-07
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor： WANG, Cheng-I , WANG, Bei , NGOH, Zi Xian Eve , LEE, Wen-Hsin , HU, Yuanyu , LEE, Chia Yin , TAN, Hwee Ching , NG, Patricia Miang Lon , MINHAT, Rabiatul Adawiyah Binte , HUANG, Ching-Wen , SOH, Mun Kuen , YEAP, Yee Chin, Yvonne , TEO, Jiuyi Frannie
Abstract: The present invention relates to provide antigen-binding proteins that are capable of binding to and/or neutralizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In one embodiment, the antigen-binding proteins are capable of binding to a spike protein of SARS-CoV-2 including receptor-binding domain (RBD) of SARS-CoV-2. The present invention also provides products comprising the same and methods of using the same for the treatment of SARS-CoV-2 infection or for detecting the presence of SARS-CoV-2 in a sample.
-
Patent Agency Ranking
公开(公告)号：WO2020190217A3
公开(公告)日：2020-09-24
申请号：PCT/SG2020/050152
申请日：2020-03-22
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor： WANG, Cheng-I , WANG, Bei , NGOH, Zi Xian Eve , LEE, Wen-Hsin , HUANG, Ching-Wen , YEAP, Yee Chin, Yvonne
IPC: C07K16/28 , C07K14/705 , A61K39/395 , A61K35/17 , G01N33/577 , A61P35/00
Abstract: We describe an antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) sequence and a light chain variable region (VL) sequence of a clone selected from: 5C4, 4H1, 1D2, 1C4, 2B5, 1F1, 1H1, 4A5, 1D8, 1D3, 2F1, 3C6, 3D12, 3A9, 1F4, 1H10, 3C12, 4G11, 4A12, 1A12, 3G12, 4F9, 4G4 and 1E1 which is capable of specifically binding to glypican-3 (GPC-3) (GenBank Accession Number: NP_004475.1), or a sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto.
-
公开(公告)号：WO2019160501A1
公开(公告)日：2019-08-22
申请号：PCT/SG2019/050077
申请日：2019-02-12
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor： WANG, Cheng-I , LOW, Lionel Jianrong , GOH, Angeline
IPC: C07K16/30 , A61K39/395 , G01N33/53 , A61P35/00
Abstract: The current invention relates to anti-HER2 monoclonal antibodies and chimeric antigen receptors comprising anti-HER2 antigen-binding domains. In particular, the disclosed antibodies are capable of inducing apoptosis in HER2-expressing cells. The current invention also relates to a pharmaceutical composition comprising said antibodies and its use thereof to treat cancer.
-
公开(公告)号：WO2017194265A1
公开(公告)日：2017-11-16
申请号：PCT/EP2017/058956
申请日：2017-04-13
Inventor： WANG, Cheng-I , NGOH, Eve , YEO, Siok Ping
IPC: C07K16/28
Abstract: Anti-CTLA-4antibodies are disclosed. Also disclosed are compositions comprising such antibodies, and uses and methods using the same.
Abstract translation: 公开了抗CTLA-4抗体。 还公开了包含此类抗体的组合物，以及使用它们的用途和方法。
-
9.发明申请A SEROTYPE CROSS-REACTIVE, DENGUE NEUTRALIZING ANTIBODY AND USES THEREOF 审中-公开SEROTYPE CROSS-REACTIVE，DENGUE NEURTRALIZING ANTIBODY AND USES THEREOF
公开(公告)号：WO2016148653A1
公开(公告)日：2016-09-22
申请号：PCT/SG2016/050124
申请日：2016-03-17
Inventor： WANG, Cheng-I , FINK, Katja , MACARY, Paul , ZUEST, Roland , XU, Meihui
IPC: C07K16/10 , A61K39/42 , A61P31/12 , G01N33/569
CPC classification number: C07K16/1081 , A61K2039/505 , A61P31/12 , C07K2317/34 , C07K2317/76 , G01N33/56983 , G01N2333/185 , Y02A50/386 , Y02A50/53
Abstract: Disclosed are isolated antibodies, or antigen binding fragments thereof, that bind to dengue virus epitopes, as well as kits containing them, compositions containing them, and passive vaccines comprising them, in one embodiment, the antibody or antigen binding fragment thereof is capable of binding to a whole dengue virus particle better than binding to a dengue virus surface glycoprotein. Also disclosed are methods of using the antibodies or antigen binding fragments thereof, nucleic acids encoding them, vectors expressing the nucleic acids, host producing them, and methods of manufacturing them.
Abstract translation: 公开了与登革热病毒表位结合的分离的抗体或其抗原结合片段，以及含有它们的试剂盒，含有它们的组合物，以及包含它们的被动疫苗，在一个实施方案中，抗体或其抗原结合片段能够结合 对整个登革热病毒颗粒比结合登革病毒表面糖蛋白更好。 还公开了使用抗体或其抗原结合片段，编码它们的核酸，表达核酸的载体，产生它们的宿主及其制备方法。
-
公开(公告)号：WO2016111645A1
公开(公告)日：2016-07-14
申请号：PCT/SG2016/050001
申请日：2016-01-04
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor： WANG, Cheng-I , OH, Hsueh Ling Janice , YEO, Siok Ping
IPC: C07K16/28 , A61K39/395 , A61P37/02
CPC classification number: A61K39/3955 , A61K39/395 , A61K45/06 , A61K2039/505 , C07K14/70532 , C07K16/2827 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/567 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/30 , G01N33/53 , G01N33/57484 , G01N2800/52 , Y02A50/41 , Y02A50/412
Abstract: Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and methods of using such antibodies to restore T-cell function in T-cells exhibiting T-cell exhaustion or T-cell anergy.
Abstract translation: 公开了抗-PD-L1抗体。 还公开了包含这种抗体的药物组合物，以及使用这些抗体来恢复显示T细胞耗尽或T细胞无反应性的T细胞中T细胞功能的方法。
-
-
-
-
-
-
-
-
-
Search Results
42
records
(took 0.037 seconds)
